PRNewswire (Thu, 26-Mar 8:00 AM ET)
PRNewswire (Wed, 25-Mar 8:30 AM ET)
IceCure Appoints Meir Peleg as Chief Financial Officer
PRNewswire (Tue, 24-Mar 8:30 AM ET)
IceCure Reports 2025 Full Year Financial & Operational Results
PRNewswire (Tue, 17-Mar 8:30 AM ET)
PRNewswire (Wed, 11-Mar 8:30 AM ET)
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026
PRNewswire (Tue, 10-Mar 8:30 AM ET)
PRNewswire (Mon, 9-Mar 8:30 AM ET)
PRNewswire (Mon, 2-Mar 8:30 AM ET)
PRNewswire (Mon, 23-Feb 8:30 AM ET)
PRNewswire (Thu, 19-Feb 8:30 AM ET)
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Icecure Medical Ltd. - trades on the NASDAQ stock market under the symbol ICCM.
As of April 2, 2026, ICCM stock price was flat at $0.30 with 513,718 million shares trading.
ICCM has a beta of 0.78, meaning it tends to be less sensitive to market movements. ICCM has a correlation of 0.03 to the broad based SPY ETF.
ICCM has a market cap of $24.35 million. This is considered a Sub-Micro Cap stock.
Last quarter Icecure Medical Ltd. - reported $1 million in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-21,000 and missed earnings estimates by -$.02.
In the last 3 years, ICCM traded as high as $1.66 and as low as $.28.
ICCM has underperformed the market in the last year with a price return of -75.8% while the SPY ETF gained +18.2%. ICCM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -50.8% and -50.0%, respectively, while the SPY returned -3.6% and -0.6%, respectively.
ICCM support price is $.28 and resistance is $.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICCM shares will trade within this expected range on the day.